phosphorylates the 3 ' hydroxyl group of the aminohexose I of 
neomycin and its analogues, inactivating the antibiotic. While 
amikacin may be inactivated by this enzyme, gentamicin and 
tobramycin do not contain an hydroxyl at the 3' position and are 
not inactivated. Therefore, introduction of the NeoR gene would 
not exclude the use of aminoglycosides or any other conventional 
antibiotic that may be needed in the clinical management of these 
patients . 
Although risks to the patient exist in this study, they 
would appear to be minimal, and the nature of the vectors and 
concurrent medications should minimize the risks to any 
individual patient. Because there are no curative treatments for 
these patients, these risks are thought to be justified, 
considering the potential therapeutic benefit, either to them or 
to future patients. 
[26] 
Recombinant DNA Research, Volume 18 
